ATF6

Across TCGA pan-cancer cohorts, ATF6 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ATF6 data layer compared with 27 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ATF6 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ATF6 expression acts as an unfavorable survival marker, although some lineages such as LUAD and HNSC show a favorable association.

LUAD, LSCC, and HNSC are the cancer types where ATF6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	III,IV	0.890	0.249	.011	20	view →
LSCC	DFS	Quartile	All	0.592	0.920	.005	5	view →
HNSC	OS	Median	III,IV	0.747	0.492	.044	1	view →
CCRCC	DFS	Median	III,IV	0.697	0.921	.038	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ATF6–LUAD (DFS)

Open the LUAD breakdown →